BioPharmSignal logoBioPharmSignal

Biotech News

Supernus Announces Record Fourth Quarter and Full Year 2025 Financial Results

Supernus (SUPN)SupernusEarnings

Record total revenues of $211.6 million and $719.0 million in the fourth quarter and full year 2025, a 21% and 9% increase compared to same periods last year. Combined revenues of the Company's four growth products increased to $161.3 million and $521.8 million in the fourth quarter and full year

Related news

SUPNSupernus2026-07-22 21:05 EST

Supernus Pharmaceuticals to Announce Second Quarter 2026 Financial Results and Host Conference Call on August 4, 2026

SUPNSupernus2026-08-03 10:35 EST

Supernus Announces Second Quarter 2026 Financial Results

CLNNClene Inc.2026-08-14 12:30 EST

Clene Reports Second Quarter 2026 Financial Results and Recent Operating Highlights

TNXPTonix Pharmaceuticals2026-08-10 11:00 EST

Tonix Pharmaceuticals Reports Second Quarter 2026 Financial Results and Operational Highlights

AXSMAxsome2026-08-10 11:00 EST

Axsome Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update

DNLIDenali Therapeutics2026-08-06 20:01 EST

Denali Therapeutics Reports Second Quarter 2026 Financial Results and Business Highlights

VYGRVoyager Therapeutics2026-08-06 20:01 EST

Voyager Reports Second Quarter 2026 Financial and Operating Results

BCLIBrainstorm Cell Therapeutics Inc.2026-08-14 20:00 EST

BrainStorm Cell Therapeutics Announces Second Quarter 2026 Financial Results and Provides Corporate Update

ANVSAnnovis Bio2026-08-14 12:00 EST

Annovis Provides Corporate Updates and Second Quarter 2026 Financial Results

NGENNervGen Pharma2026-08-13 11:30 EST

NervGen Reports Second Quarter 2026 Financial Results and Provides Business Updates

View all latest news

Supernus

CNS Commercial Portfolio Supernus Pharmaceuticals develops and commercializes treatments for central nervous system disorders. Its marketed portfolio spans attention-deficit hyperactivity disorder, Parkinson’s disease, postpartum depression, epilepsy, migraine, cervical dystonia and chronic sialorrhea. Growth Products The company’s...

Recent company news

SUPNSupernus2026-08-03 10:35 EST

Supernus Announces Second Quarter 2026 Financial Results

SUPNSupernus2026-08-03 10:30 EST

Supernus Pharmaceuticals and Indivior Pharmaceuticals to Merge, Creating a Diversified CNS Biopharmaceutical Leader with Significant Scale

SUPNSupernus2026-07-22 21:05 EST

Supernus Pharmaceuticals to Announce Second Quarter 2026 Financial Results and Host Conference Call on August 4, 2026

SUPNSupernus2026-07-14 12:30 EST

Supernus Celebrates Five-Year Anniversary of Qelbree® FDA Approval, Continuing to Deliver on Real-World Experience in ADHD

SUPNSupernus2026-05-27 20:30 EST

Supernus Pharmaceuticals to Participate in June Investor Conferences

Stock data

Close
45.85 USD
Market cap
2.56B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States